1 / 10

US 6,743,786 Vanadium Compounds for Treating Cancer

US 6,743,786 Vanadium Compounds for Treating Cancer. Chrissy Brown (PO) Lisa Perlson (AI) November 15, 2006. PO. Claimed Invention: VCp 2 (bpy)OTf 2. Abbreviations V – Vanadium(IV) Cp – Cyclopentadienyl Ring Bpy – 2,2’-Bipyridine OTf 2 – Triflate (CF 3 SO 3 - ).

newman
Download Presentation

US 6,743,786 Vanadium Compounds for Treating Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. US 6,743,786Vanadium Compounds for Treating Cancer Chrissy Brown (PO) Lisa Perlson (AI) November 15, 2006

  2. PO Claimed Invention: VCp2(bpy)OTf2 Abbreviations V – Vanadium(IV) Cp – Cyclopentadienyl Ring Bpy – 2,2’-Bipyridine OTf2 – Triflate (CF3SO3- ) • Used to treat Leukemia, Hodgkin’s Lymphoma, non-Hodgkin’s Lymphoma, Multiple Myeloma, Testicular Cancer, Brain Tumor, Breast Cancer and Prostate Cancer

  3. PO Anticancer Activity of VCp2Cl2 • VCp2Cl2 and TiCp2Cl2 are well known anti-cancer agents. • Comparable activity in mammary, lung, colon and skin cancer • For testicular, brain and leukemia cancers, only V showed anti- cancer activity (Unexpected Result) In Vitro Cytotoxicity of Vanadocene Compounds Against Human Cancer • VDC = VCp2Cl2

  4. PO Monodentate v. Bidentate VCp2 Ligands • Monodenate Ligands • Single Coordination to Metal • Ex: Cl, CN, SCN • Bidentate Ligands • Double Coordination to Metal • Ex: Bipyridine Proposed Binding of VCp2X2 to DNA V • VCp2 have loose interaction with PO4 Group • VCp2(bpy) dissociates differently than VCp2Cl2 • VCp2(bpy) binds DNA differently leading to a different mode of activity?

  5. PO Anticancer Activity of VCp2(bpy) • Many VCp2(chelator) compounds synthesized in 1960-1975. • No Reported Biological Activity • First Reported Synthesis of VCp2(byp)compound • VCp2(byp) has high efficacy with low dosage (Unexpected Result) In Vitro Cytotoxicity of Vanadocene Compounds Against Human Cancer

  6. PO Claimed Invention: VCp2(bpy)OTf2 • Patentability of Claim 5 • In certain tumors, VCp2Cl2 is the only Metal-Cp2Cl2 complex to demonstrate anti-cancer activity. • This unexpected result implies a new reactivity for V complexes toward these cancer and nullifies any previous assumptions about other ligands. • Synthesis of VCp2(bpy)OTf2 was previously unreported in the literature • VCp2(bpy)OTf2 shows high efficacy of cancer cell death with low doses compared to other VCp2(chelator) ligands.

  7. AI Claimed Invention: VCp2(bpy)OTf2 • Invalidity of Claim 5: Obviousness • Synthesis of VCp2(bpy)OTf2 was obvious to POSITA from published analogous synthesis of TiCp2(bpy)OTf2. • Substitution of V for Ti is common in studies of metallocene complexes, so there is motivation to combine in the prior art. • TiCp2(bpy)OTf2 showed anti-cancer activity, so it is not an unexpected result for VCp2(bpy)OTf2 to show anti-cancer activity.

  8. AI Synthesis of VCp2(bpy)OTf2 • 2 step synthesis of TiCp2(bpy)OTf2 published in 1986 (J. Organometallic Chem. 1986, 302, 193.) • Patent acknowledges using “modified” TiCp2(bpy)(OTf2)2 synthesis • VCp2X2 and TiCp2X2 are commonly made using the same procedure, as would be known by POSITA. • VCp2Cl2 and TiCp2Cl2 are commercially available. TiCp2(bpy)(OTf2)2

  9. AI Metallocenes with Antitumor Activity • Examiner failed to take into account prior art for VCp2X2 compounds when considering application.

  10. AI Activity Against Fluid Ehrlich Ascites Tumor Optimum Dose Range = 40 – 60 mg/kgCure Rate = 100% Optimum Dose Range = 80 – 90 mg/kg Cure Rate = 100% Optimum Dose Range = ? Cure Rate = ? Optimum Dose Range = 140 – 220 mg/kg Cure Rate = 100%

More Related